蛋白质特征对酶抑制剂中活性悬崖的倾向有很大影响
1Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Sciences Private University, Amman, Jordan. s_daoud@asu.edu.jo.
Scientific reports
|April 20, 2024
概括
活性悬崖 (ACs),在此类分子具有不同的向亲和力,是药物发现的挑战. 这项研究发现,特定的蛋白质特征,而不仅仅是结合点,预测蛋白质激酶中的ACs,帮助计算药物设计.
科学领域:
- 药用化学 医学化学
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
背景情况:
- 活动悬崖 (ACs) 代表结构相似的化合物具有不同的生物活动,使药物发现复杂化.
- 蛋白激酶是关键的治疗点,但有些表现出ACs,阻碍了抑制剂的发展.
- 了解ACs的决定因素对于推进计算机辅助药物设计至关重要.
研究的目的:
- 为了研究蛋白质特性与蛋白质激酶中活性悬崖的发生之间的关系.
- 为了确定与ACs的存在或不存在相关的特定蛋白质结构特征.
- 通过预测和减轻ACs来增强药物发现的计算方法.
主要方法:
- 机器学习模型的开发,以将蛋白质特性与ACs相关联.
- 分析蛋白质特性,包括结合部位和整体结构背景.
- 评估与ACs相关的三序列和全球蛋白质特征.
主要成果:
- 蛋白激酶中的特定三序列被确定为影响ACs的关键因素.
- 除了直接结合部位之外,蛋白质的整体特性与ACs发生有显著的相关性.
- 机器学习模型成功地将蛋白质特征与AC联系起来,证明了预测能力.
结论:
- ACs的存在取决于目标蛋白的完整结构上下文,而不仅仅是其结合点.
- 确定关键蛋白质特征可以指导更有效的激酶抑制剂的设计.
- 这项研究提供了一种新的计算策略,用于解决药物发现和开发中的AC.
相关概念视频
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Enzyme Inhibition
78.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.3K
Receptor Tyrosine Kinases
12.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.8K


